UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NetEase
NTES
|
+$336M |
| 2 |
AbbVie
ABBV
|
+$235M |
| 3 |
VMW
VMware, Inc
VMW
|
+$163M |
| 4 |
T-Mobile US
TMUS
|
+$156M |
| 5 |
Aptiv
APTV
|
+$154M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$570M |
| 2 |
Microsoft
MSFT
|
+$506M |
| 3 |
Apple
AAPL
|
+$394M |
| 4 |
Abbott
ABT
|
+$262M |
| 5 |
Intel
INTC
|
+$244M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.77% |
| 2 | Healthcare | 13.92% |
| 3 | Consumer Discretionary | 13.52% |
| 4 | Financials | 11.89% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRSN
1676
DELISTED
Mersana Therapeutics
MRSN
| $1.22M | ﹤0.01% |
+2,085
| New | +$712K |
|
1677
Akebia Therapeutics
AKBA
$252M
| $1.21M | ﹤0.01% |
89,187
+10,058
| +13% | +$104K |
|
1678
Yext
YEXT
$574M
| $1.2M | ﹤0.01% |
72,472
-11,873
| -14% | -$166K |
|
1679
Sonos
SONO
$1.85B
| $1.2M | ﹤0.01% |
82,273
-422,735
| -84% | -$4.49M |
|
1680
Invesco Mortgage Capital
IVR
$805M
| $1.2M | ﹤0.01% |
32,105
+6,489
| +25% | +$223K |
|
1681
Comfort Systems
FIX
$59.6B
| $1.2M | ﹤0.01% |
29,409
-5,131
| -15% | -$182K |
|
1682
Palomar
PLMR
$3.45B
| $1.2M | ﹤0.01% |
13,958
+2,558
| +22% | +$170K |
|
|
ITCI
1683
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.2M | ﹤0.01% |
46,588
+45
| +0.1% | +$911 |
|
|
ESPR
1684
DELISTED
Esperion Therapeutics
ESPR
| $1.19M | ﹤0.01% |
23,208
+3,904
| +20% | +$163K |
|
1685
Liberty Latin America Class C
LILAK
$1.64B
| $1.19M | ﹤0.01% |
146,694
-4,853
| -3% | -$41.3K |
|
|
AVYA
1686
DELISTED
Avaya Holdings Corp. Common Stock
AVYA
| $1.18M | ﹤0.01% |
95,498
-8,840
| -8% | -$102K |
|
1687
Addus HomeCare
ADUS
$2.23B
| $1.18M | ﹤0.01% |
12,735
+923
| +8% | +$79.8K |
|
1688
Gentherm
THRM
$1.27B
| $1.17M | ﹤0.01% |
30,102
-2,848
| -9% | -$108K |
|
1689
Cerence
CRNC
$413M
| $1.17M | ﹤0.01% |
28,625
-31,127
| -52% | -$894K |
|
1690
ICF International
ICFI
$1.72B
| $1.17M | ﹤0.01% |
18,022
-1,016
| -5% | -$66.6K |
|
1691
MacroGenics
MGNX
$257M
| $1.16M | ﹤0.01% |
41,655
-600,094
| -94% | -$10.4M |
|
1692
Greif
GEF
$5.04B
| $1.16M | ﹤0.01% |
33,770
-563
| -2% | -$18.5K |
|
1693
Kulicke & Soffa
KLIC
$4.78B
| $1.16M | ﹤0.01% |
55,508
-1,234
| -2% | -$27.9K |
|
|
PRFT
1694
DELISTED
Perficient Inc
PRFT
| $1.15M | ﹤0.01% |
32,200
-559
| -2% | -$18.5K |
|
|
MINI
1695
DELISTED
Mobile Mini Inc
MINI
| $1.15M | ﹤0.01% |
38,950
-11,531
| -23% | -$344K |
|
1696
Cytokinetics
CYTK
$10.4B
| $1.14M | ﹤0.01% |
48,409
-10,952
| -18% | -$205K |
|
1697
McGrath RentCorp
MGRC
$2.92B
| $1.14M | ﹤0.01% |
21,048
-5,152
| -20% | -$277K |
|
|
GNMK
1698
DELISTED
GenMark Diagnostics, Inc
GNMK
| $1.13M | ﹤0.01% |
76,692
+9,252
| +14% | +$94K |
|
1699
HNI Corp
HNI
$3.59B
| $1.13M | ﹤0.01% |
36,806
-13,003
| -26% | -$331K |
|
1700
MaxLinear
MXL
$6.8B
| $1.13M | ﹤0.01% |
52,429
-10,403
| -17% | -$179K |
|
Similar funds
UBS AM's Q2 2020 Portfolio in Review
As of Q2 2020, UBS AM held 2,605 positions worth $164B, up 18% from $139B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
UBS AM withdrew a net $6.16B in Q2 2020, closing 142 positions and reducing 1,290 holdings. Its most notable exit was Allergan plc, an estimated $203M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, UBS AM opened a new position in Otis Worldwide worth $76.5M.
- UBS AM's largest Q2 2020 buy was Otis Worldwide: 1,345,382 shares worth $76.5M.
- UBS AM added most to NetEase in Q2 2020, an estimated $336M increase.
- UBS AM's biggest Q2 2020 reduction was Alibaba, cutting an estimated $570M.
- UBS AM fully exited Allergan plc in Q2 2020, selling an estimated $203M.
- UBS AM's ten largest holdings make up 24% of its $164B portfolio in Q2 2020.
- UBS AM opened 144 new positions and closed 142 in Q2 2020.
- UBS AM's portfolio value rose 18% quarter-over-quarter to $164B.
Based on UBS AM's 13F filing for Q2 2020, filed 14 Aug 2020.